Deutsche Märkte geschlossen

Celyad Oncology SA (CLYYF)

Other OTC - Other OTC Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
4,65000,0000 (0,00%)
Ab 11:37AM EST. Markt geöffnet.

Celyad Oncology SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter95

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BMECo-Founder, CFO, Interim CEO & Director83,78kN/A1956
Mr. David GeorgesVP of Fin. & Admin.N/AN/AN/A
Sara ZelkovicCommunications & Investor Relations DirectorN/AN/AN/A
Mr. Philippe NobelsChief HR Officer & VP of HRN/AN/A1966
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.Chief Medical OfficerN/AN/A1965
Ms. An PhanHead of LegalN/AN/AN/A
Mr. Hannes IserentantHead of Intellectual PropertyN/AN/AN/A
Dr. Frédéric LehmannVP of Clinical Devel. & Medical AffairsN/AN/A1964
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate Governance

Celyad Oncology SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.